Abstract
MET amplification (METamp) is a mechanism of acquired resistance to EGFR-TKIs. In the INSIGHT trial (NCT01982955), in patients with EGFR-mutant METamp NSCLC and EGFR-TKI resistance, tepotinib (a potent, highly selective MET-TKI) plus gefitinib (EGFR-TKI) improved outcomes in comparison with chemotherapy. We present a case series highlighting the clinical activity of tepotinib plus an EGFR-TKI (gefitinib and/or osimertinib) in patients with EGFR-mutant METamp NSCLC.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
